CLICK HERE to watch the recorded webinar
Blended Learning Journey on Cardiovascular disease and hypertension 2024
Beta-blockers are recommended by the most recent European guidelines (McDonagh et al. 2021, Knuuti et al. 2020) as first-line therapy for coronary artery disease and heart failure with reduced ejection fraction. However, physicians underuse these drugs in patients who present with co-existing comorbidities but who are not contraindicated, which can negatively affect patient outcomes and long-term prognoses (Paolillo et al. 2021). The increasing prevalence of heart failure, with its high morbidity and mortality rate, has highlighted the need for more education about accurate differential diagnosis and management. Arterial hypertension and hypercholesterolemia increase the likelihood of cardiovascular disease, but early detection of these conditions is low due to inadequate screening, insufficient assessment, poor management, and poor treatment adherence (Tadic and Cuspidi 2019, Mach et al. 2020). Education and support of both healthcare professionals and patients, particularly women transitioning to menopause, is important in understanding risk-reducing strategies, healthy behaviours and treatment adherence. Ever-increasing pressures on healthcare professionals may only be met with innovations, including embracing both telemedicine and telemonitoring, both of which have shown promise for hypertension management (Omboni et al. 2020).
At the end of the blended learning journey, participants will be able to:
Clinicians (including cardiologists, internists, and general practitioners), nurse practitioners and other HCPs who manage patients with hypertension and heart failure. Some content of interest to gynaecologists, midwives, nurses involved in women’s health care.
The official language of this educational programme will be English. Simultaneous translation into Russian and Chinese will be provided.
The BLENDED LEARNING JOURNEY ON CARDIOVASCULAR DISEASE AND HYPERTENSION 2024 will be submitted for CME accreditation from the European Accreditation Council for Continuing Medical Education (EACCME), and/ or the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) and for Continuing Professional Development (CPD) credits.
Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996. His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 60 countries and has published 482 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.
Felix Mahfoud is professor of medicine and deputy director of the Department for Internal Medicine and Cardiology at Saarland University Hospital and Visiting Professor at Harvard-MIT, Biomedical Engineering, Boston, MA. From June 1st, Felix Mahfoud will serve as Head of Department and Professor of Cardiology at University Basel, Switzerland. Professor Mahfoud holds board certifications in internal medicine, cardiology, intensive care medicine, emergency medicine, and hypertension. He is member of several editorial boards and serves as Secretary of the Council on Hypertension of the European Society of Cardiology (ESC)‚ PCR Board of Director and program committee member (topic coordinator hypertension) of the ESC congress 2023 & 2024. He has authored more than 460 articles in peer reviewed journals and was writing committee member of the 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes, the 2018 ESC/ESH Guidelines for the management of arterial hypertension, and the 2023 ESH Guidelines for the management of arterial hypertension.
Maria Lorenza Muiesan has been full Professor of Internal Medicine, at the Department of Clinical and Experimental Sciences at the University of Brescia since 2005. She is Chairman of the Department of Internal Medicine, ASST Spedali Civili di Brescia. Prof Muiesan graduated in Medicine and Surgery at the University of Milan in 1980, she specialized in Cardiology (1982) and Internal Medicine (1987) at the University of Milan. She has spent few years in prestigious international Research Centers as visiting Research Fellow with the support of institutional grants (MRC, Great Britain), in London, GB, Hammersmith Hospital (1982-1983), in New York, Cornell University (1994), US. Prof Muiesan has lectured internationally on topics related to hypertension and cardiovascular diseases of the European Society of Hypertension, and of the European Society of Cardiology. She is a member of several national and international Scientific Societies (including Societ Italiana della Ipertensione Arteriosa, Societ Italiana di Medicina Interna, Societ Italiana di Cardiologia, European Society of Hypertension, International Society of Hypertension, European Society of Cardiology). Prof Muiesan is currently President of the Italian Society of Hypertension. She is also member of the Council of Hypertension of the European Society of Cardiology. Prof Muiesan has also participated in several randomized multicentre clinical trials in cardiovascular care, and has actively participated to the prospective large observational Vobarno study in East Lombardia (Italy). Scientific Referee or Editorial Board Member of several scientific journals: Hypertension, Circulation, European Heart Journal, Italian Journal of Cardiology, J. Hypertension, Blood Pressure, European Journal of Internal Medicine, Frontiers in Cardiovascular Diseases, Journal of Human Hypertension, Int J Cardiology, High Blood Pressure and CV Prevention). Author of about 800 scientific publications – H-index 56.
Stefano Taddei is Full Professor of Internal Medicine, currently working as Director of the Hypertension Unit at the Department of Clinical and Experimental Medicine of the University of Pisa, Italy. He is a fellow of the European Society of Cardiology, member of the European, International and American Society of Hypertension, the European Society of Clinical Investigation and the High Blood Pressure Council of the American Heart Association. Professor Taddei is an editorial board member for numerous international and national scientific journals, Hypertension, Journal of Hypertension, Journal of Cardiovascular Pharmacology, Blood Pressure and he is Deputy Editor of the European Heart Journal. His main research area is the neuro-humoral control of peripheral arterial circulation in essential and secondary hypertension, with particular emphasis on adrenergic mechanisms, non-adrenergic neurotransmitters, the circulating and vascular renin-angiotensin system and endothelial function. Professor Taddei has participated in numerous clinical studies and is the authors of more than 400 original papers, reviews editorials and book chapters in international scientific journals (H index: 74; Impact Factor: >3000).
Harry Struijker-Boudier is emeritus professor of pharmacology at Maastricht University in the Netherlands and former director of the Cardiovascular Research Institute Maastricht. His scientific career focused on cardiovascular pharmacology and pharmacotherapy, in particular in the area of hypertension. He was member and vice-chairman of the Scientific Council of the European Society of Hypertension as well as board member of the European Federation of Pharmacological Societies and the council member of the International Society of Vascular Health. In addition to his position at Maastricht University he held appointments as visiting professor at several universities in the United States, Asia and Europe. At present he is chairman of the Scientific Board of the Paris Cardiovascular Research Center and the Nancy Cardiovascular Research Center in France. He (co)authored more than 500 papers in international journals and books on cardiovascular diseases and their treatment. The total number of citations of these papers is >40,000. He is doctor honoris causa of the Université de Liège in Belgium, recipient of the Descartes-Huygens prize of the French Government and Officer of the Order of Oranje-Nassau of the Dutch Royal House.
Brian Tomlinson is Professor in the Faculty of Medicine at Macau University of Science & Technology since 2019 and Consultant at the University Hospital in Macau. He was previously Professor of Medicine and Therapeutics in the Department of Medicine and Therapeutics from 2007 until 2015 and Head of the Division of Clinical Pharmacology from 2003 at the Chinese University of Hong Kong. He was Honorary Consultant Physician at the Prince of Wales Hospital, Hong Kong from 1990 to 2019. He trained as a specialist in Internal Medicine and Clinical Pharmacology at the Middlesex Hospital and University College London and he has a particular clinical and research interest in lipid disorders, hypertension, diabetes and cardiovascular disease. He has participated in many early phase clinical trials with various types of medication and in later phase international trials in hyperlipidaemia, hypertension and diabetes. He is an author on over 500 publications in peer-reviewed journals. He is currently the Chair of the Asia-Pacific Federation of the International Atherosclerosis Society and is a Past-President of the Asian-Pacific Society of Atherosclerosis and Vascular Diseases.
Stay in the know with our CME updates
